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ABSTRACT
Background: Bronchiolitis obliterans syndrome (BOS) is the term used for the progressive obliteration of small airways before the patient has 
had a confirmatory lung biopsy. It is also recognized as a transplant-related complication. There have been no reports of BOS during initial 
standard chemotherapy. 
Case presentation: A 50-year-old woman with newly diagnosed follicular lymphoma grade 2, stage 3A, presented with hypoxia and progressive 
dyspnoea after the fifth cycle of R-CHOP. High-resolution computed tomography showed air trapping enhanced at the end-expiratory phase. 
Pulmonary function testing revealed severe obstructive and restrictive failure without bronchodilator response. We diagnosed BOS based 
on current criteria and treated the patient with glucocorticoids and cyclosporin. She was discharged home on oxygen therapy. However, 
soon after discharge, her respiratory symptoms deteriorated and she was hospitalized in a palliative care unit. She died of respiratory failure 
within a year of symptom onset.
Conclusions: This is the first case report to describe rapidly progressive BOS in a patient undergoing R-CHOP treatment, which strongly 
suggests the condition was caused by the chemotherapy. Although a pathological diagnosis was not obtained, the clinical diagnosis of BOS 
was important so that the patient could receive appropriate treatment and palliative care based on the prognosis of this incurable condition.
LEARNING POINTS
• R-CHOP chemotherapy may cause rapidly progressive bronchiolitis obliterans syndrome (BOS).
• When it is difficult to obtain a pathological diagnosis, a clinical diagnosis of BOS is important for early intervention and appropriate 
palliative care.
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CASE DESCRIPTION 
A 50-year-old Japanese woman was admitted to the authors’ hospital for further investigation of hypoxia and progressive dyspnoea. She had 
been newly diagnosed with follicular lymphoma (FL) grade 2, stage 3A, and had started standard dose R-CHOP (rituximab, cyclophosphamide, 
doxorubicin, vincristine and prednisolone) chemotherapy 4 months previously. She had developed non-productive cough and dyspnoea on 
exertion after the fifth cycle without chest radiographic or echocardiographic abnormality. On the sixth (final) cycle, she presented with 
hypoxia and deteriorating symptoms. 
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The patient’s medical history was unremarkable, except for FL. She had no history of allergy. She had never smoked and had not been 
exposed to dust or toxic chemicals. She did not regularly take any prescription or non-prescription medicine. 
She was afebrile and her respiratory rate was 20 breaths/min. Oxygen saturation was 89% on room air and 98% on 3 l/min oxygen, but had 
been normal (98% on room air) just before chemotherapy. Arterial blood gas analysis revealed hypoxaemia, while other laboratory data 
were unremarkable (Table 1). Breath sounds were decreased in the bilateral lower lung fields. 
Complete blood count Biochemistry Immunology
Arterial blood gas analysis 
02 1.5 l/min
WBC 10,040 /μl Na 143 mEq/l IgG 598 mg/dl Ph 7.434
Neutrophil 86% K 4.1 mEq/l IgA 67 mg/dl PO2 95.6 mmHg
Lymphocyte 6.2% Cl 102 mEq/l IgM 43 mg/dl PCO2 46.3 mmHg
Monocyte 6.8% UN 10 mg/dl C3 69.6 U/ml HCO3 31 mmol/l
Eosinophil 0.7% Cre 0.58 mg/dl C4 45 mg/dl SO2 97.4%
Basophil 0.3% AST 24 U/l CH50 69.6 U/ml Pulmonary function test
RBC 4.08x104 /μl ALT 23 U/l Anti nuclear
 antibody
<40x Actual 
value
Predicted 
value
Hb 11.5 g/dL γGTP 20 U/l Anti AchR antibody Negative FVC 1.241 43.9
Ht 37.7% LDH 248 U/l C-ANCA Negative FEV 1.0 0.44 l 18.7
Plt 56.4x104 /μl CRP 0.33 mg/dl P-ANCA Negative FEV 1.0% 35.5%
Coagulation
TP 6.5 g/dl Anti demosglein-1 
antibody 
Negative FEV 1.0/VC 16.7 %
PT-INR 1.03 Alb 3.4 g/dl Anti demosglein-1
 antibody
Negative
APTT 27 s CK 73 U/l Anti BP180 antibody Negative
Fib 539 mg/dl KL-6 256 U/ml C7-HRP Negative
D-Dimer 0.71μg/ml sIL-2R 401 U/ml B-D Glucan Negative
Chest radiography revealed a dropped heart and a hyperinflated lung which developed after symptom onset (Fig. 1). CT of the whole 
body showed bulky intraperitoneal lymph nodes reduced in size, with other previously enlarged lesions now normalized (Fig. 2). High-
resolution CT (HRCT) of the chest revealed bronchial dilatation and a mosaic pattern consisting of high- and low-density areas that 
represented bronchiolar air trapping, which was enhanced at the end-expiratory phase, although CT of the chest before chemotherapy had 
not demonstrated abnormal findings (Fig. 3). Pulmonary function testing (PFT) revealed severe obstructive and restrictive failure (forced 
expiratory volume in 1 s, 19% of predicted; forced vital capacity, 43.9% of predicted) without bronchodilator response (Fig. 4). 
Figure 1. Chest radiographs showing a dropped heart 
and lung hyperinflation which appeared soon after 
symptom onset. CTR: cardiothoracic ratio
Table 1. Laboratory findings
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Figure 2. CT of the abdomen showing intraperitoneal lymph nodes still present but 
reduced in size
Figure 3. CT of the chest showing a mosaic pattern of air trapping enhanced at the 
expiratory phase (chest CT before chemotherapy was normal)
Figure 4. Pulmonary function testing with a bronchodilator revealing severe obstructive 
and restrictive failure without bronchodilator response
Figure 5. Pulmonary ventilation and perfusion scintigraphy revealing a mosaic pattern of 
radio-isotope uptake decrease without ventilation-perfusion mismatch
The patient was certain her PFT results had been normal several years previously. Pulmonary ventilation and perfusion scintigraphy revealed 
a mosaic pattern of radio-isotope uptake decrease without ventilation-perfusion mismatch (Fig. 5).
BO was strongly suspected clinically and these results met the current criteria for BOS[1]. A lung biopsy for the diagnosis of BO was not 
performed due to the patient’s poor performance status and the risk of serious respiratory injury being caused by the surgical procedure. 
The patient was diagnosed with BOS after other differential diseases had been excluded. 
Steroid pulse therapy (methylprednisolone 1 g/day) was administered for 3 days, followed by prednisolone 1 mg/kg. The patient was also 
treated with low-dose oral azithromycin and inhalation of tiotropium. However, she developed respiratory failure on exertion and required 
positive pressure ventilation support twice during a 1-month period. Steroid pulse therapy was repeated and cyclosporine was added. Her 
respiratory condition stabilised and she was discharged home on oxygen therapy. However, soon after discharge, her respiratory symptoms 
deteriorated and she was hospitalized in a palliative care unit. The patient died of respiratory failure within a year of symptom onset.
DISCUSSION
The clinical course of this patient shows that she developed BOS rapidly during R-CHOP therapy with no association with transplantation 
or any other known cause(s), which strongly suggests that chemotherapy can cause BOS.
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BO is recognized as a manifestation of chronic graft-versus-host disease in patients who have undergone HSCT[2, 3]. However, some agents 
and diseases can also cause lung injury that results in BO. Examples include inhalation of nitrogen oxides or diacetyl, Sauropus androgynus 
consumption, respiratory infection and autoimmune diseases, such as rheumatic diseases and paraneoplastic pemphigus (PNP)[4–11]. BO is 
rarely caused by drugs, with reports limited to gold and penicillamine[12, 13]. A direct causal relationship with rituximab, cyclophosphamide, 
doxorubicin and vincristine has not been described. 
There was a previous case report of BO after rituximab-containing chemotherapy. A 63-year-old woman with FL who was treated with six 
cycles of R-CHOP, developed progressive airflow obstruction 3 years after the last treatment and was diagnosed with BO 2 years later[14]. 
Our patient rapidly developed BOS during R-CHOP chemotherapy and quickly deteriorated, which was totally different from the case 
described above. Chest imaging with radiography, CT and PFT indicated her symptoms presented after initiation of chemotherapy. There 
were no other definitive causes and concomitant idiopathic BOS was unlikely. PNP-related BO in patients with malignant lymphoma has 
been reported[7]. However, our patient never exhibited evidence of PNP physically or serologically (Table 1). Therefore, our case strongly 
suggests that the occurrence of BOS was related to therapy, which was also different from the case above. 
The diagnosis of BO usually requires an open or thoracoscopic lung biopsy, although this is often inadequate for diagnosis due to patchy 
distribution of the lesion. Because lung biopsy is often difficult for patients with pulmonary failure, it is now considered that in a high-
probability clinical setting, such as a known predisposing inhalational exposure or transplantation, the combination of airflow limitation on 
PFT and typical HRCT findings, such as expiratory air trapping and bronchial wall thickening, may be sufficient to make the diagnosis. The 
International Society for Heart and Lung Transplantation proposed the term ‘BOS’ as the clinical diagnosis for post-transplanted patients 
with the aim of early diagnosis and intervention [15, 16]. The diagnosis of BOS requires the careful exclusion of other differential diagnoses. The 
clinical manifestations in our case did not follow a typical pattern for asthma or COPD because the patient was a non-smoker and airflow 
limitation was irreversible. Other diseases, such as interstitial pneumonia, organizing pneumonia, hypersensitivity pneumonitis, sarcoidosis 
and pulmonary embolism, were excluded due to absence of typical findings. Because our patient met the current criteria for BOS (1, 2, 3 
and 4b)[1], we diagnosed her with BOS to allow early intervention and treatment. R-CHOP is standard chemotherapy for de novo malignant 
lymphoma of B-cell origin, including FL. Therefore, in similarly treated non-transplant patients, BOS should be included in the differential 
diagnosis for new respiratory symptoms. Although BOS in some patients is progressive and fatal, despite all therapies, clinical diagnosis 
enables us to provide appropriate treatment and palliative care.
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